Treating critical illness: The importance of first doing no harm

PLoS Medicine

Volumn 2, Issue 6, 2005, Pages 0497-0502

  Singer, Mervyn ^a   Glynne, Paul ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOGLYCOSIDE DERIVATIVE; AMIODARONE; ANTIBIOTIC AGENT; BACTERICIDE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CATECHOLAMINE DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DOBUTAMINE; DOPAMINE; ETOMIDATE; FUROSEMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; INHALATION ANESTHETIC AGENT; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NORADRENALIN; OPIATE DERIVATIVE; PENICILLIN DERIVATIVE; PROPOFOL; PROTON PUMP INHIBITOR; ROFECOXIB; SEDATIVE AGENT;

ACUTE HEART FAILURE; AMPUTATION; ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; ASEPSIS; BACTERIAL GROWTH; BIOFILM; BLOOD TRANSFUSION; CLINICAL TRIAL; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DEVICE; DIET; DRUG SURVEILLANCE PROGRAM; EUTHYROID SICK SYNDROME; EXERCISE; FEEDING BEHAVIOR; FORWARD HEART FAILURE; FUNGUS GROWTH; GANGRENE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH EDUCATION; HEART ARRHYTHMIA; HUMAN; HYGIENE; HYPOVOLEMIA; INFLAMMATION; INTENSIVE CARE; LIFE EXPECTANCY; MEASLES; METABOLIC DISORDER; MORTALITY; MUMPS; NEUROMUSCULAR DISEASE; NUTRITION; POLLUTION; PUBLIC HEALTH; SANITATION; SHORT SURVEY; SIDE EFFECT; SMOKING; SURVIVAL; TETANUS; THROMBOSIS; TYPHOID FEVER; TYPHUS; VASOCONSTRICTION; WAR; WEANING; ARTICLE; DRUG EFFECT; DRUG INTERACTION; DRUG THERAPY; EVIDENCE BASED MEDICINE; HISTORY; METHODOLOGY; MITOCHONDRION; SEPSIS;

AMPUTATION; BLOOD TRANSFUSION; CARDIAC OUTPUT, LOW; CRITICAL CARE; CRITICAL ILLNESS; DRUG INTERACTIONS; DRUG THERAPY; EVIDENCE-BASED MEDICINE; HISTORY, 19TH CENTURY; HUMANS; MITOCHONDRIA; RESPIRATION, ARTIFICIAL; SEPSIS;

EID: 22144445679     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020167     Document Type: Short Survey

References (72)

1. Lewis M (2004) The social history of the navy 1793-1815. Mechanicsburg (Pennsylvania): Stackpole Books. 467 p.
2. Beatty W (1805) List of wounded at Battle of Trafalgar. Available: http://www.nationalarchives.gov.uk/pathways/battles/trafalgar/ts13a.htm. Accessed 22 April 2005.
3. Barrett CRB (1911) The 13th at Waterloo. Available: http://www. pinetreeweb.com/waterloo.htm. Accessed 22 April 2005.
4. United States Civil War Center (2001) Statistical summary of America's major wars. Available: http://www.cwc.lsu.edu/cwc/ other/stats/warcost.htm. Accessed 22 April 2005.
5. Adams GW (1996) Doctors in blue: The medical history of the Union Army in the Civil War. Baton Rouge (Louisiana): Louisiana State University Press. 253 p.
6. Armstrong GL, Conn LA, Pinner RW (1999) Trends in infectious disease mortality in the United States during the 20th century. JAMA 281: 61-66.
7. Arias E (2004) United States life tables, 2002. Natl Vital Stat Rep 53: 29.
8. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, et al. (2004) Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 364: 2021-2029.
9. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, et al. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32: 858-873.
10. 2 Collaborative Group. N Engl J Med 333: 1025-1032.
11. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, et al. (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330: 1717-1722.
12. Hebert PC, Wells G, Blajchman MA (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Canadian Critical Care Trials Group. N Engl J Med 340: 409-417.
13. The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301-1308.
14. Northridge D (1996) Frusemide or nitrates for acute heart failure? Lancet 347: 667-668.
15. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, et al. (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26: 384-416.
16. Cotter G, Metzkor E, Kaluski E (1998) Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351: 389-393.
17. Clutter WE, Bier DM, Shah SD, Cryer PE (1980) Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic action in man. J Clin Invest 66: 94-101.
18. Nikolaidis LA, Hentosz T, Doverspike A, Huerbin R, Stolarski C, et al. (2002) Catecholamine stimulation is associated with impaired myocardial O2 utilization in heart failure. Cardiovasc Res 53: 392-404.
19. Bergmann M, Sautner T (2002) Immunomodulatory effects of vasoactive catecholamines. Wien Klin Wochenschr 114: 752-761.
20. Arcaroli J, Yang KY, Yum HK, Kupfner J, Pitts TM, et al. (2002) Effects of catecholamines on kinase activation in lung neutrophils after hemorrhage or endotoxemia. J Leukoc Biol 72: 571-579.
21. Levy B, Mansart A, Bollaert PE, Franck P, Mallie JP (2003) Effects of epinephrine and norepinephrine on hemodynamics, oxidative metabolism, and organ energetics in endotoxemic rats. Intensive Care Med 29: 292-300.
22. Lyte M, Freestone PP, Neal CP, Olson BA, Haigh RD, et al. (2003) Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropes. Lancet 361: 130-135.
23. Freestone PP, Williams PH, Haigh RD, Maggs AF, Neal CP, et al. (2002) Growth stimulation of intestinal commensal Escherichia coli by catecholamines: A possible contributory factor in trauma-induced sepsis. Shock 18: 465-470.
24. Cuffe MS, Califf RM, Adams KF Jr (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 287: 1541-1547.
25. Cohn JN, Goldstein SO, Greenberg BH (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 339: 1810-1816.
26. Follath F, Cleland JG, Just H, Papp JG, Scholz H, et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 360: 196-202.
27. Coletta AP, Cleland JG, Freemantle N, Clark AL (2004) Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail 6: 673-676.
28. Rybak MJ (2004) Resistance to antimicrobial agents: An update. Pharmacotherapy 24: 203S-215S.
29. Kress JP, Pohlman AS, O'Connor MF, Hall JB (2000) Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 342: 1471-1477.
30. Brealey D, Brand M, Hargreaves I, Heales S, Land J, et al. (2002) Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360: 219-223.
31. Brealey D, Karyampudi S, Jacques TS, Novelli M, Stidwill R, et al. (2004) Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 286: R491-R497.
32. Boulos M, Astiz ME, Barua RS, Osman M (2003) Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Crit Care Med 31: 353-358.
33. Singer M, De Santis V, Vitale D, Jeffcoate W (2004) Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 364: 545-548.
34. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, et al. (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27: 1230-1251.
35. Prins JM, van Deventer SJ, Kuijper EJ, Speelman P (1994) Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother 38: 1211-1218.
36. Lepper TK, Held EM, Schneider E, Bolke H, Gerlach M, et al. (2002) Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 28: 824-833.
37. Heer C, Stuertz K, Reinert RR, Mader M, Nau R (2000) Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trova. oxacin. Infection 28: 13-20.
38. van Langevelde P, van Dissel JT, Ravensbergen E, Appelmelk BJ, Schrijver IA, et al. (1998) Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob Agents Chemother 42: 3073-3078.
39. Riesbeck K, Bredberg A, Forsgren A (1990) Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrob Agents Chemother 34: 167-169.
40. Wilkie D (1977) Mitochondrial biogenesis: Inhibitors of mitochondrial protein synthesis. Mol Cell Biochem 14: 97-100.
41. Mela-Riker LM, Widener LL, Houghton DC, Bennett WM (1986) Renal mitochondrial integrity during continuous gentamicin treatment. Biochem Pharmacol 35: 979-984.
42. Tune BM, Hsu CY (1990) The renal mitochondrial toxicity of beta-lactam antibiotics: In vitro effects of cephaloglycin and imipenem. J Am Soc Nephrol 1: 815-821.
43. Hosein EA, Lapalme M, Sacks B, Wiseman-Distler M (1979) Biphasic changes in rat brain mitochondrial membrane structure and enzyme activity after acute opiate administration to rats. Biochem Pharmacol 28: 7-14.
44. Colleoni M, Costa B, Gori E, Santagostino A (1996) Biochemical characterization of the effects of the benzodiazepine, midazolam, on mitochondrial electron transfer. Pharmacol Toxicol 78: 69-76.
45. Stevanato R, Momo F, Marian M, Rigobello MP, Bindoli A, et al. (2002) Effects of nitrosopropofol on mitochondrial energy-converting system. Biochem Pharmacol 64: 1133-1138.
46. Kupriyanov VV, Lakomkin VL, Korchazhkina OV, Stepanov VA, Steinschneider AY (1991) Cardiac contractile function, oxygen consumption rate and cytosolic phosphates during inhibition of electron flux by amytal - a 31P-NMR study. Biochim Biophys Acta 1058: 386-399.
47. Miro O, Barrientos A, Alonso JR, Casademont J, Jarreta D, et al. (1999) Effects of general anaesthetic procedures on mitochondrial function of human skeletal muscle. Eur J Clin Pharmacol 55: 35-41.
48. Vasile B, Rasulo F, Candiani A, Latronico N (2003) The pathophysiology of propofol infusion syndrome: A simple name for a complex syndrome. Intensive Care Med 29: 1417-1425.
49. Larsen B, Hoff G, Wilhelm W, Buchinger H, Wanner GA, et al. (1998) Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood. Anesthesiology 89: 1218-1227.
50. Song HK, Jeong DC (2004) The effect of propofol on cytotoxicity and apoptosis of LPS-treated mononuclear cells and lymphocytes. Anesth Analg 98: 1724-1728.
51. Brand JM, Frohn C, Luhm J, Kirchner H, Schmucker P (2003) Early alterations in the number of circulating lymphocyte subpopulations and enhanced proinflammatory immune response during opioid-based general anesthesia. Shock 20: 213-217.
52. Helmy SA, Al-Attiyah RJ (2001) The immunomodulatory effects of prolonged iv infusion of propofol versus midazolam in critically ill surgical patients. Anaesthesia 56: 4-8.
53. Kelbel I, Koch T, Weber A, Schiefer HG, van Ackern K (1999) Alterations of bacterial clearance induced by propofol. Acta Anaesthesiol Scand 43: 71-76.
54. Delogu G, Antonucci A, Moretti S, Marandola M, Tellan G, et al. (2004) Oxidative stress and mitochondrial glutathione in human lymphocytes exposed to clinically relevant anesthetic drug concentrations. J Clin Anesth 16: 189-194.
55. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, et al. (1997) Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 3: 678-681.
56. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA (2004) Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 11: 161-167.
57. Watt I, Ledingham IM (1984) Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 39: 973-981.
58. Absalom A, Pledger D, Kong A (1999) Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 54: 861-867.
59. Bailey AR, Burchett KR (1997) Effect of lowdose dopamine on serum concentrations of prolactin in critically ill patients. Br J Anaesth 78: 97-99,
60. Zellweger R, Zhu XH, Wichmann MW, Ayala A, DeMaso CM, et al. (1996) Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol 157: 5748-5754.
61. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, et al. (2000) A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283: 1038-1045.
62. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862-871.
63. De Jonghe B, Sharshar T, Lefaucheur JP (2002) Paresis acquired in the intensive care unit: A prospective multicenter study. JAMA 288: 2859-2867.
64. Leon-Sanz M, Lorente JA, Larrodera L, Ros P, Alvarez J, et al. (1997) Pituitary-thyroid function in patients with septic shock and its relation with outcome. Eur J Med Res 2: 477-482.
65. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, et al. (1999) Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial. JAMA 282: 54-61.
66. Bertolini G, Iapichino G, Radrizzani D, Facchini R, Simini B, et al. (2003) Early enteral immunonutrition in patients with severe sepsis: Results of an interim analysis of a randomised multicentre clinical trial. Intensive Care Med 29: 834-840.
67. Health Canada (2005) Notice to hospitals: Health Canada endorsed important safety information on Xigris. Available: http://www.hc-sc.gc.ca/hpfb- dgpsa/tpd-dpt/xigris_nth_e.pdf. Accessed 22 April 2005.
68. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, et al. (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292: 1555-1562.
69. Hebert PC, Fergusson D, Blajchman MA (2003) Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 289: 1941-1949.
70. Leontiadis GI, Sharma VK, Howden CW (2005) Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 330: 568.
71. [No authors listed] Human albumin administration in critically ill patients: Systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ 317: 235-240.
72. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, et al. (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350: 2247-2256.